# Cambrooke Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cambrooke-therapeutics

- Industry: Healthcare
- Headquarters: Ayer, US
- Website: www.cambrooke.com
- Total disclosed funding: $8M
- Latest round: Series C (Apr 11, 2016)
- Investors on record: 2

## About

Cambrooke Therapeutics, Inc. specializes in advanced medical nutrition, focusing on therapeutic nutritional solutions tailored for patients with specific chronic medical conditions.Cambrooke Therapeutics, Inc. was founded in 2000 in Ayer, US, and is known for developing medical nutrition products. The company was acquired by Ajinomoto Co., Inc. in November 2017 for USD 64 mn. Lynn Paolella is the founder, while Howard Lossing serves as the current CEO.Cambrooke Therapeutics, Inc. specializes in advanced medical nutrition, offering a range of nutritional therapeutic options designed to address specific chronic medical needs. Their core product offerings include specialized formulas such as Glytactin and Tylactin, which are tailored for patients with conditions like Phenylketonuria (PKU) and Maple Syrup Urine Disease (MSUD). These products aim to improve patient satisfaction and clinical outcomes by providing effective dietary management solutions that allow users to maintain a balanced diet while adhering to their medical restrictions. The company serves a diverse clientele, including healthcare providers, hospitals, and patients across various geographical markets such as the United States, Canada, and select international regions. Cambrooke products have been recognized for their quality, receiving certifications such as OU Dairy certification from the Orthodox Union, further establishing their credibility within the medical community.Cambrooke Therapeutics, Inc. generates revenue through direct-to-consumer sales as well as partnerships with healthcare professionals and institutions. Their business model involves the distribution of specialized medical nutrition products, which may be purchased directly by patients or prescribed by healthcare providers. This dual channel allows the company to reach both end-users and institutional clients effectively. Flagship products such as Tylactin RTD and Glytactin RTD facilitate recurring purchases due to their necessity in managing specific dietary restrictions. The pricing structure encompasses individual product sales, potentially offering different pricing tiers based on the product type or packaging. This approach enables Cambrooke to cater to a broad spectrum of patients, from those requiring basic nutritional support to individuals with more complex dietary needs.Following the acquisition in November 2017, Cambrooke Therapeutics, Inc. plans to utilize the funding from the acquisition to enhance its product development strategy. The company is focused on designing new medical nutrition products aimed at addressing broader dietary needs and expanding its reach into additional international markets by 2025.

## Funding rounds

- Series C, Apr 11, 2016 — Galen Partners, Seventure Partners
- Series A, Mar 1, 2011, $8M — Galen Partners

## Investors

- Galen Partners (https://capitalatlas.ai/funds/galen-partners) — Series A, Series C
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series C